[Lesson from ACR guidelines for management of RA].
Abe
Toru
T
Saitama Medical Center/School.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D008727:Methotrexate / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012219:Rheumatology; D012955:Societies, Medical; D014481:United States
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068800:Etanercept; D008727:Methotrexate